期刊
OCULAR SURFACE
卷 16, 期 3, 页码 368-376出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jtos.2018.05.001
关键词
Dry eye disease; Tear biomarkers; Environmental conditions; Clinical trial endpoint; Cytokine
资金
- Consejeria de Educacion, Castilla y Leon Council [VA174U14]
- European Social Funds, Operative Program for Castilla y Leon, Castilla y Leon Council, Spain [EDU/346/2013]
- Allergan, Irvine, CA, USA
Purpose: To evaluate the effect of 0.1%-fluorometholone (FML) on tear inflammatory molecule levels after 22-days treatment in dry eye disease (DED) patients exposed to an adverse controlled environment (ACE), identifying different biomarkers. Methods: Analysis of a double-masked randomized clinical trial. Forty-one DED patients received 4-drops daily of topical FML (FML-group) or polyvinyl-alcohol (PA-group) for 22 days. At day 21, patients were exposed to an ACE. Tear samples were collected at V1 (baseline), V2 (pre-ACE), V3 (post 2 h ACE) and V4 (24-h post-ACE). Concentrations of 18 molecules (EGF, IFN-gamma, TNF-alpha, IL-1 beta, IL-1RA, IL-2, IL-4, IL-6, IL-8/CXCL8, IL-10, IL-12, IL-13, IL-17A, IP-10/CXCL10, MCP-1/CCL2, MIP-1a/CCL3, RANTES/CCL5 and MMP-9) were analyzed. Similarities among patients in molecule concentrations at V1 were evaluated. A linear-mixed effect model analyzed the influence of different variables on concentrations changes. Results: Multidimensional scaling (MDS) divided patients into two groups based on differences in EGF, IFN-gamma, IL-8/CXCL8, RANTES/CCL5, and MMP-9 levels at V1. Groups had different clinical severities based on Schirmer test and conjunctival and corneal staining. IL-1RA, IL-2, and TNF-alpha were differentially affected by time, depending on treatment. Between V2-V3, there were significant changes in EGF, IL-1RA, IL-2, IL-8/CXCL8, IL-13, IP-10/CXCL10, TNF-alpha, and MMP-9. The strongest biomarker candidates were IFN-gamma, RANTES/CCL5, and MMP-9 as DED severity biomarkers; IL-2 as DED therapeutic biomarker; and EGF as DED activity biomarker. Conclusions: This clinical trial design using a controlled environment and the identified tear biomarkers could be useful to objectively select target patients, to define stress response, and to evaluate therapeutic endpoints in clinical trials.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据